The Release of Platelet-Activating Factor during Phagocytosis by Polymorphonuclear Neutrophils and Monocytes

  • G. Camussi
  • F. Bussolino
  • M. Aglietta
  • W. Piacibello
  • C. Tetta
  • G. Segoloni
  • R. A. Clark
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 141)


Platelet-activating factor (PAF) is a soluble factor that induces platelet aggregation and release reaction (1–4), independently from ADP- and Arachidonic Acid/Thromboxane A2 -mediated pathways (2, 4). PAF is alow molecular weight phospholipid (1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine)(5,6). PAF was initially obtained from antigen-stimulated, IgE-sensitized rabbit basophils (2). In man PAF release from basophils still awaits confirmatory evidence, mainly because in man basophils constitute a much smaller fraction of the total leukocytes than in the rabbit. Lewis recovered a PAF-like activity from purified leukemic basophils in the presence of Calcium Ionophore (7). Later, we have shown that immune complexes (IC), the specific antigen, anaphylatoxin and neutrophil cationic proteins stimulate PAF release from human leukocytes (8). Although basophil degranulation was coincident with PAF release, the cell populations used in those experiments were relatively impure. More recently, ultrastructural evidence of platelet interaction only with degranulated basophils but not with either neutrophils or monocytes was obtained when basophils were degranulated by the specific antigen, anti-IgE or Synachten (9). However, PAF release occurred independently from basophil degranulation during phagocytosis by polymorphonuclear neutrophils (PMN) and monocytes (9,10). Lotner et al. demonstrated that purified human PMN are capable of releasing PAF (11). The purpose of the present report was to comparatively study the mechanism of PAF release from PMN and monocytes under phagocytic stimuli.


Platelet Activate Factor Rhizopus Arrhizus Basophil Degranulation Lysosomal Enzyme Release Membrane Phospholipase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    P.M. HENSON and C.G. COCHRANE: Immune complex disease in rabbits. The role of complement and of a leukocyte-dependent release of vasoactive amines from platelets. J.Exp.Med. 133: 554 (1971).PubMedCrossRefGoogle Scholar
  2. 2).
    J. BENVENISTE, P.M. HENSON and C.G. COCHRANE: Leukocyte-dependent, histamine release from rabbit platelets: the role of IgE, basophils and platelet-activating factor. J.Exp.Med. 136: 1356 (1972).PubMedCrossRefGoogle Scholar
  3. 3).
    J. BENVENISTE: Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature (Loud.) 249: 581 (1974).CrossRefGoogle Scholar
  4. 4).
    M. CHIGNARD, J.P. COUEDIC, M. TENCE, B.B. VARGAFTIG and J. RENVENISTE: The role of platelet-activating factor in platelet aggregation. Nature (Loud.) 279: 799 (1979).CrossRefGoogle Scholar
  5. 5).
    J. BENVENISTE, M. TENCE, J. BIDAULT, C. BOULLET and J. POLONSKY: Sémi-synthèse et structure proposée du facteur activant les plaquettes (PAF): PAF-acether, un alkyl ether analogue de le lysophosphatidylcholine. C.R.Acad.Sci. (Paris), 289: 1037 (1979).Google Scholar
  6. 6).
    C.A. DEMOPOULOS, R.N. PINCKARD and D.J. HANAHAN: Platelet-activating factor. Evidence for a 1–0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J.Biol.Chem. 254, 9355 (1979).PubMedGoogle Scholar
  7. 7).
    R.A. LEWIS, E.J. GOETZL, S.J. WASSERMAN, S.I. VALLONE, R.H. RUBIN and K.F AUSTEN: The release of four mediators of immediate hypersensitivity from human leukemic basophils. J.Immunol. 114: 87 (1975).PubMedGoogle Scholar
  8. 8).
    G. CAMUSSI, J.M. MENCIA-HUERTA and J. BENVENISTE: Release of platelet activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils, Immunology 33: 523 (1977).PubMedGoogle Scholar
  9. 9).
    G. CAMUSSI, M. AGLIETTA, R. CODA, F. BUSSOLINO, W. PIACIBELLO and C. TETTA: Release of platelet activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1980) in press.Google Scholar
  10. 10).
    G. CAMUSSI, F. BUSSOLINO, C. TETTA, J. BENVENISTE and A. VERCELLONE: Platelet-activating factor and glomerulonephritis. In Hemostasis, Prostaglandins and Renal Disease’) Eds. G.Remuzzi et al., Raven Press New York, 133, 1980.Google Scholar
  11. 11).
    G.Z. LOTNER, J.M. LYNCH, S.J. BETZ and P.M. HENSON. Human neutrophil derived platelet’activating factor. J.Immunol. 124: 676 (1980).PubMedGoogle Scholar
  12. 12).
    G. CAMUSSI, C. TETTA, F. BUSSOLINO, F.C. CAPPIO, R. CODA, C. MASERA and G. SEGOLONI: Mediators of immune complex-induced aggregation of polymorph.onuclear neutrophils. I.C5a Anaphylatoxin, Neutro-phil Cationic Proteins and Their Cleavage Fragments. Int.Archs Allergy appl.Immun. 62: 1–15 (1980).CrossRefGoogle Scholar
  13. 13).
    J. BENVENISTE, G. CAMUSSI, J. POLONSKY: PLatelet-activating factor. Monogr.Allergy 12: 138 (1977).PubMedGoogle Scholar
  14. 14).
    J. BENVENISTE, J.P. COUEDIC, J. POLONSKY and M. TENCE. Structural analysis of purified platelet activating factor by lipases. Nature (Lond.) 269: 180 (1977).CrossRefGoogle Scholar
  15. 15).
    F. RUFF, A. SANDELLE, E. DUTRIPAN and J.L. PARROT: Continous automatic fluorimetric, evaluation of total blood histamine. Nature (Lond.) 214: 279 (1967).CrossRefGoogle Scholar
  16. 16).
    W.E. WACKER, D.D. ULMER and B. VOLEE. Metalloenzymes and myocardial infarction. New Engl.J.Med. 225: 449 (1956).CrossRefGoogle Scholar
  17. 17).
    G. BRITTINGER, R. HIRSCHORN, S.D. DOUGLAS and G. WEISSMAN: Studies on lysosomes. XI. Characterization of hydrolase-rich fraction from human lymphocytes. J.Cell.Biol. 37: 394 (1968).PubMedCrossRefGoogle Scholar
  18. 18).
    D.J. PROCKOP and W.P. DAVIDSON: A study of urinary and serum lysozyme in patients with renal disease. New Engl.J.Med. 270: 269, 1964PubMedCrossRefGoogle Scholar
  19. 19).
    R.M. PINCKARD, R.S. FARR and D.S. HANAHAN: Physicochemical and fun ctional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE-sensitized basophils. J.Imuunol. 123, 1847 (1979).Google Scholar
  20. 20).
    J.J. GODFROID, F. HEYMANS, E. MICHEL, C. REDEVILH, E. STEINER and J. BENVENISTE: Platelet-activating factor (PAF-acether): total synthesis of 1–0-octadecyl-2–0 -acetyl-sn-glycero-3-phosphorylcholine, FEBS Letters 116: 161 (1980).PubMedCrossRefGoogle Scholar
  21. 21).
    D.J. HANAHAN, C.A. DEMOPOULOS, J. LIEHR and R.N. PINCKARD: Identification of PF isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. J.Biol.Chem. 25: 5514 (1980).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • G. Camussi
    • 1
  • F. Bussolino
    • 1
  • M. Aglietta
    • 2
  • W. Piacibello
    • 2
  • C. Tetta
    • 1
  • G. Segoloni
    • 1
  • R. A. Clark
  1. 1.Laboratorio di ImmunopatologiaCattedra di NefrologiaTorinoItaly
  2. 2.Cattedra di Patologia Medica ITorinoItaly

Personalised recommendations